Sign In
Buy ALT
$2.99
-0.0600 (-1.97%)
At Close: Jul 13, 2026
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
10:16am, Tuesday, 07'th Jul 2026
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolut
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
06:01am, Friday, 26'th Jun 2026
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
09:41am, Thursday, 25'th Jun 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
12:31pm, Friday, 12'th Jun 2026
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
10:32am, Wednesday, 10'th Jun 2026
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
09:05am, Wednesday, 10'th Jun 2026
Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company's focus on pemvidutide, its lead metabolic and liver disease drug candidate
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
01:11pm, Monday, 08'th Jun 2026
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
ALT and the Rise of Dual Agonists Targeting Liver Disease
01:11pm, Monday, 08'th Jun 2026
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
12:55pm, Monday, 08'th Jun 2026
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
11:10pm, Thursday, 04'th Jun 2026
Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatoh
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
12:00pm, Saturday, 30'th May 2026
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors
Altimmune to Participate in Upcoming Investor Conferences
08:30am, Wednesday, 27'th May 2026
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today annou
